Patents by Inventor Swann Gaulis

Swann Gaulis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MARKERS ASSOCIATED WITH HUMAN DOUBLE MINUTE 2 INHIBITORS
    Publication number: 20160289770
    Abstract: The invention provides methods of monitoring differential gene expression of biomarkers to determine patient sensitivity to Human Double Minute inhibitors (MDM2i), methods of determining the sensitivity of a cell to an MDM2i by measuring biomarkers and methods of screening for candidate MDM2i.
    Type: Application
    Filed: May 18, 2016
    Publication date: October 6, 2016
    Applicant: Novartis AG
    Inventors: Swann Gaulis, Sebastien Jeay
  • Markers associated with human double minute 2 inhibitors
    Patent number: 9371568
    Abstract: The invention provides methods of monitoring differential gene expression of biomarkers to determine patient sensitivity to Human Double Minute inhibitors (MDM2i), methods of determining the sensitivity of a cell to an MDM2i by measuring biomarkers and methods of screening for candidate MDM2i.
    Type: Grant
    Filed: July 25, 2013
    Date of Patent: June 21, 2016
    Assignee: Novartis AG
    Inventors: Swann Gaulis, Sebastien Jeay
  • MARKERS ASSOCIATED WITH HUMAN DOUBLE MINUTE 2 INHIBITORS
    Publication number: 20150159222
    Abstract: The invention provides methods of monitoring differential gene expression of biomarkers to determine patient sensitivity to Human Double Minute inhibitors (MDM2i), methods of determining the sensitivity of a cell to an MDM2i by measuring biomarkers and methods of screening for candidate MDM2i.
    Type: Application
    Filed: July 25, 2013
    Publication date: June 11, 2015
    Applicant: NOVARTIS AG
    Inventors: Swann Gaulis, Sebastien Jeay
  • MARKERS ASSOCIATED WITH HUMAN DOUBLE MINUTE 2 INHIBITORS
    Publication number: 20140038986
    Abstract: The invention provides methods of monitoring differential gene expression of biomarkers to determine patient sensitivity to Human Double Minute inhibitors (MDM2i), methods of determining the sensitivity of a cell to an MDM2i by measuring biomarkers and methods of screening for candidate MDM2i.
    Type: Application
    Filed: July 25, 2013
    Publication date: February 6, 2014
    Inventors: Swann Gaulis, Sebastien Jeay
  • Method for Classifying Cancer Patients as Responder or Non-Responder to Immunotherapy
    Publication number: 20100247580
    Abstract: The present invention relates to gene expression profiles; methods for classifying patients; microarrays; and treatment of population of patients selected through use of methods and microarrays as described herein.
    Type: Application
    Filed: November 27, 2008
    Publication date: September 30, 2010
    Inventors: Thierry Coche, Swann Gaulis, Jamila Louahed